12/5
10:04 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $564.00 price target on by analysts at Morgan Stanley.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $564.00 price target on by analysts at Morgan Stanley.
12/4
01:41 pm
vrtx
Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates [Yahoo! Finance]
Low
Report
Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates [Yahoo! Finance]
12/4
10:07 am
vrtx
Harding Loevner Global Equity's Views on Vertex Pharmaceuticals Incorporated (VRTX) [Yahoo! Finance]
Low
Report
Harding Loevner Global Equity's Views on Vertex Pharmaceuticals Incorporated (VRTX) [Yahoo! Finance]
12/3
02:21 pm
vrtx
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today [Yahoo! Finance]
Low
Report
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today [Yahoo! Finance]
12/3
11:26 am
vrtx
Vertex Pharmaceuticals' Kidney Pipeline Seen as Growth Driver, Morgan Stanley Says [Yahoo! Finance]
Low
Report
Vertex Pharmaceuticals' Kidney Pipeline Seen as Growth Driver, Morgan Stanley Says [Yahoo! Finance]
12/3
08:44 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
Medium
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
11/28
05:32 pm
vrtx
Ontario woman who fought for cystic fibrosis drug recognized for increasing access [Globe and Mail, The (Toronto, Canada)]
Low
Report
Ontario woman who fought for cystic fibrosis drug recognized for increasing access [Globe and Mail, The (Toronto, Canada)]
11/28
09:37 am
vrtx
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq? [Yahoo! Finance]
Low
Report
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq? [Yahoo! Finance]
11/28
02:23 am
vrtx
Where Will Vertex Pharmaceuticals Be in 5 Years [Yahoo! Finance]
Low
Report
Where Will Vertex Pharmaceuticals Be in 5 Years [Yahoo! Finance]
11/27
10:35 pm
vrtx
Kidney Disease Trial Success Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX) [Yahoo! Finance]
Low
Report
Kidney Disease Trial Success Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX) [Yahoo! Finance]
11/21
09:06 pm
vrtx
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why [Yahoo! Finance]
Low
Report
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why [Yahoo! Finance]
11/19
04:00 pm
vrtx
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
Low
Report
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
11/18
12:58 pm
vrtx
Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings [Yahoo! Finance]
Low
Report
Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings [Yahoo! Finance]
11/18
05:03 am
vrtx
Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target [Yahoo! Finance]
Low
Report
Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target [Yahoo! Finance]
11/14
07:54 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
11/13
09:53 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $495.00 price target on the stock.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $495.00 price target on the stock.
11/11
02:43 pm
vrtx
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/11
08:28 am
vrtx
Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development [Yahoo! Finance]
Low
Report
Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development [Yahoo! Finance]
11/10
09:40 pm
vrtx
The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress [Yahoo! Finance]
Low
Report
The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress [Yahoo! Finance]
11/10
03:48 am
vrtx
5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q3 Earnings Call [Yahoo! Finance]
Low
Report
5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q3 Earnings Call [Yahoo! Finance]
11/9
01:18 am
vrtx
Vertex Pharmaceuticals Incorporated (VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio Transcript [Seeking Alpha]
Low
Report
Vertex Pharmaceuticals Incorporated (VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio Transcript [Seeking Alpha]
11/8
05:25 pm
vrtx
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week [Yahoo! Finance]
Low
Report
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week [Yahoo! Finance]
11/8
05:15 pm
vrtx
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
Low
Report
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
11/7
01:43 pm
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target lowered by analysts at UBS Group AG from $553.00 to $546.00. They now have a "buy" rating on the stock.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target lowered by analysts at UBS Group AG from $553.00 to $546.00. They now have a "buy" rating on the stock.
11/4
09:25 pm
vrtx
Vertex Pharmaceuticals (VRTX) Returns to Profitability, Challenging Bearish Narratives on Earnings Quality [Yahoo! Finance]
Low
Report
Vertex Pharmaceuticals (VRTX) Returns to Profitability, Challenging Bearish Narratives on Earnings Quality [Yahoo! Finance]